Ipsen has avoided an interruption in US supply of Increlex (IGF-1) to treat Severe Primary IGF-1 Deficiency due to delays in manufacturing site approval. Ipsen has worked in close relation with the US Food and Drug Administration to ...
Tags: Ipsen, Increlex Supply, Severe Primary IGF-1 Deficiency